Hyperprogression of submandibular melanoma following pembrolizumab therapy

Oral Oncol. 2023 Jan:136:106279. doi: 10.1016/j.oraloncology.2022.106279. Epub 2022 Dec 13.

Authors

Amr Muhammed¹, Esraa Elnakib², Walaa Gamal³, Shimaa Roshdy³, Aya Mahmoud³, Aya Ahmed³, Ahmed El Sayed Mohamed³

Affiliations

¹ Clinical Oncology Department, Faculty of Medicine, Sohag University Hospital, Egypt. Electronic address: amr.muhammed@med.sohag.edu.eg.
² Clinical Oncology Department, Faculty of Medicine, Sohag University Hospital, Egypt; Nuclear Medicine Department, Faculty of Medicine, Sohag University Hospital, Egypt.
³ Clinical Oncology Department, Faculty of Medicine, Sohag University Hospital, Egypt.

PMID: 36521380
DOI: 10.1016/j.oraloncology.2022.106279

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Melanoma*
Skin Neoplasms*

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized